FIG. 5.
Ultrasound and 18FDG-PET scan of patient with melanoma and papillary thyroid cancer (A) demonstrating regression in size and resolution of 18FDG avidity of papillary thyroid cancer one year after Pembrolizumab therapy for melanoma (B). 18FDG, 18-fluorodeoxy glucose; PET, positron emission tomography.